BRIEF-Novo Nordisk CEO: It Will Be A Long Time Before Obesity Drug Wegovy Is Available In Developing Countries Due To Cold Chain, Infrastructure Problems

Novo Nordisk A/S:

* NOVO NORDISK CEO: PRIORITY FOR OBESITY DRUG WEGOVY IS "MOST VULNERABLE PATIENTS" WITH HIGH BMI AND COMORBIDITIES, NOT THOSE WHO CAN PAY OUT OF POCKET

* NOVO NORDISK CEO: IT WILL BE A LONG TIME BEFORE OBESITY DRUG WEGOVY IS AVAILABLE IN DEVELOPING COUNTRIES DUE TO COLD CHAIN, INFRASTRUCTURE PROBLEMS Source text for Eikon: Further company coverage: